newsfilter
← Latest News
PR Newswire·

YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine

YS

GAITHERSBURG, Md., Sept. 26, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,